$CLRB
Cellectar Biosciences, Inc.

2019 Q1 Form 10-K Financial Statement

#000114420419009973 Filed on February 26, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.320M $1.170M $4.820M
YoY Change -0.75% 18.18% 16.43%
% of Gross Profit
Research & Development $2.308M $1.040M $6.835M
YoY Change 8.68% -66.45% -27.79%
% of Gross Profit
Depreciation & Amortization $32.73K $30.00K $82.27K
YoY Change 89.2% -97.62% -94.68%
% of Gross Profit
Operating Expenses $2.308M $2.200M $6.835M
YoY Change 8.68% -46.21% -27.79%
Operating Profit -$3.630M -$13.33M
YoY Change 5.1% -1.99%
Interest Expense $12.17K $60.00K $29.69K
YoY Change 161.52% 500.0% 78.78%
% of Operating Profit
Other Income/Expense, Net $8.171K $91.74K
YoY Change -136.65% 137.17%
Pretax Income -$3.620M -$3.830M -$13.24M
YoY Change 4.02% -6.13% -2.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.622M -$3.830M -$13.24M
YoY Change 4.2% -6.13% -2.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$758.9K -$732.3K -$4.473M
COMMON SHARES
Basic Shares Outstanding 4.758M 4.758M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.49M $13.26M $13.26M
YoY Change 53.81% 32.47% 32.47%
Cash & Equivalents $10.49M $13.26M $13.26M
Short-Term Investments
Other Short-Term Assets $600.0K $700.0K $700.0K
YoY Change -27.71% 48.94% 48.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.09M $13.95M $13.95M
YoY Change 45.01% 33.21% 33.24%
LONG-TERM ASSETS
Property, Plant & Equipment $516.8K $543.3K $540.0K
YoY Change 124.72% 122.03% 125.0%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $18.09K $560.0K
YoY Change -37.86% 52.34% 16.67%
Total Long-Term Assets $1.456M $1.102M $1.100M
YoY Change -23.77% -54.03% -54.17%
TOTAL ASSETS
Total Short-Term Assets $11.09M $13.95M $13.95M
Total Long-Term Assets $1.456M $1.102M $1.100M
Total Assets $12.55M $15.05M $15.05M
YoY Change 31.27% 16.96% 16.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.060M $612.0K $1.540M
YoY Change 9.57% -34.41% -17.65%
Accrued Expenses $100.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $2.200M $1.622M $1.620M
YoY Change 4.25% -23.3% -23.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $170.0K $170.0K
YoY Change
Total Long-Term Liabilities $502.2K $171.0K $170.0K
YoY Change 7627.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.200M $1.622M $1.620M
Total Long-Term Liabilities $502.2K $171.0K $170.0K
Total Liabilities $2.702M $1.793M $1.790M
YoY Change 28.06% -15.3% -15.57%
SHAREHOLDERS EQUITY
Retained Earnings -$101.2M -$97.59M
YoY Change 15.24% 15.7%
Common Stock $51.00 $47.00
YoY Change 193.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.847M $13.26M $13.26M
YoY Change
Total Liabilities & Shareholders Equity $12.55M $15.05M $15.05M
YoY Change 31.27% 16.96% 16.94%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$3.622M -$3.830M -$13.24M
YoY Change 4.2% -6.13% -2.38%
Depreciation, Depletion And Amortization $32.73K $30.00K $82.27K
YoY Change 89.2% -97.62% -94.68%
Cash From Operating Activities -$2.815M -$2.740M -$11.44M
YoY Change -11.58% -3.18% 3.83%
INVESTING ACTIVITIES
Capital Expenditures $6.242K -$380.0K $385.0K
YoY Change 338.04% 11.04%
Acquisitions
YoY Change
Other Investing Activities $10.00K $60.00K
YoY Change
Cash From Investing Activities -$6.242K -$370.0K -$330.0K
YoY Change 338.04% -4.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.076M
YoY Change 85.0%
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities -811.0 0.000 15.02M
YoY Change 11.4% -100.0% 51.29%
NET CHANGE
Cash From Operating Activities -2.815M -2.740M -11.44M
Cash From Investing Activities -6.242K -370.0K -330.0K
Cash From Financing Activities -811.0 0.000 15.02M
Net Change In Cash -2.822M -3.110M 3.249M
YoY Change -11.42% -171.66% -325.92%
FREE CASH FLOW
Cash From Operating Activities -$2.815M -$2.740M -$11.44M
Capital Expenditures $6.242K -$380.0K $385.0K
Free Cash Flow -$2.822M -$2.360M -$11.83M
YoY Change -11.43% -16.61% 4.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13255616
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10006421
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
641218
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
412173
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13951834
CY2017Q4 us-gaap Assets Current
AssetsCurrent
10473594
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543339
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
244713
CY2018Q4 us-gaap Goodwill
Goodwill
0
CY2017Q4 us-gaap Goodwill
Goodwill
1675462
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
540823
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
465823
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18086
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872
CY2018Q4 us-gaap Assets
Assets
15054082
CY2017Q4 us-gaap Assets
Assets
12871464
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1543819
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1867758
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2213
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3036
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
33090
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
138944
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1622122
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2114788
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2213
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
170999
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2213
CY2018Q4 us-gaap Liabilities
Liabilities
1793121
CY2017Q4 us-gaap Liabilities
Liabilities
2117001
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
47
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
16
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108323208
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94107981
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97588343
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84349316
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
13260961
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10754463
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15054082
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12871464
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6835229
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9465666
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4820073
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4135304
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
13330764
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
13600970
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-13330764
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-13600970
CY2018 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
62050
CY2017 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
22075
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29687
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
16605
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91737
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38680
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13239027
CY2018 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2241795
CY2017 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1448945
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15480822
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15011235
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.23
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.70
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2961972
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1403132
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-13562290
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82265
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1546048
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
721209
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
758757
CY2018 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
62050
CY2017 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
22075
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
50898
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
229045
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-281396
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-258794
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451325
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11442092
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11020301
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
384993
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
346703
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
55000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-329993
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-346703
CY2018 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3036
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2727
CY2018 clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
762
CY2017 clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9075777
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4905945
CY2018 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
5949301
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2265257
CY2018 clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
0
CY2017 clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-116337
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2963259
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
86591
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15021280
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9928806
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3249195
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1438198
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10061421
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11499619
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13310616
CY2018 us-gaap Interest Paid Net
InterestPaidNet
0
CY2017 us-gaap Interest Paid Net
InterestPaidNet
364
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
43000
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
105050
CY2018Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-07-31
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1355000
CY2018Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2785000
CY2018Q3 us-gaap Share Price
SharePrice
4.00
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.00
CY2018Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16560000
CY2018Q3 clrb Net Proceeds From Issuance Or Sale Of Equity After Deducting Underwriting Discounts And Commissions And Related Offering Expenses
NetProceedsFromIssuanceOrSaleOfEquityAfterDeductingUnderwritingDiscountsAndCommissionsAndRelatedOfferingExpenses
15000000
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5318747
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
170999
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4732387
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1666144
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4732387
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1666144
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1675462
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
13539872
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7054865
CY2017 clrb Stock Issued During Period On Exercise Of Warrants Value
StockIssuedDuringPeriodOnExerciseOfWarrantsValue
2963259
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
758757
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15025078
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
721209
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-762
CY2018 us-gaap Treasury Stock Retired Par Value Method Amount
TreasuryStockRetiredParValueMethodAmount
0
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
81214
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
473462
CY2017Q4 us-gaap Other Assets
OtherAssets
466000
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12800000
CY2018 us-gaap Change In Accounting Estimate Description
ChangeInAccountingEstimateDescription
As a result, the Company reassessed the estimated useful life of the research and development assets and concluded they should be accelerated beginning on December 1, 2017 through December 31, 2017 (one month remaining life). The Company also reassessed the estimated useful life of the leasehold improvements and concluded that they should be accelerated beginning on December 1, 2017 through December 31, 2017 (one month remaining life). These reassessments of the estimated useful lives have been accounted for as changes in an estimate.
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212; Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Cash Flows for fiscal year ended December 31, 2017, to identify the long-term other assets of approximately $466,000. This change in classification does not affect previously reported cash flows from operating activities in the Consolidated Statements of Cash Flows.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> &#8212; The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates including those related to unbilled vendor amounts, share-based compensation and derivative liability valuation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> &#8212; Financial instruments that subject the Company to credit risk consist of cash and equivalents on deposit with financial institutions. The Company&#8217;s excess cash as of December 31, 2018 and 2017 is on deposit in interest-bearing transaction accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of December 31, 2018, uninsured cash balances totaled approximately $12,800,000.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
138619
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
152626
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
155403
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
158235
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
161123
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13610
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
779616
CY2018 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company has an option to extend the term of the lease for one additional 60-month period.
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1675462
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
724531
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6088502
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
181192
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5843789
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
408000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
341000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
612000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
933000
CY2018Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
332000
CY2017Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
329000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
64000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000
CY2018Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
69000
CY2017Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
87000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2688003
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
13626404
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-45138
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1969262
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2733141
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15595666
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2733141
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-15595666
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
26562715
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
24353504
CY2018Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
5439062
CY2017Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
4947879
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1589926
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
1589927
CY2018Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
5959275
CY2017Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
5772165
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1565130
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1445078
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
166793
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
103189
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
121680
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41219297
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38397026
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
89129
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
89129
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
41130168
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
38397026
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41130168
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38397026
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 clrb Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
-0.2100
CY2017 clrb Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
0.3400
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0027
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0958
CY2018 clrb Effective Income Tax Rate Reconciliation Permanent Adjustment
EffectiveIncomeTaxRateReconciliationPermanentAdjustment
0.0256
CY2017 clrb Effective Income Tax Rate Reconciliation Permanent Adjustment
EffectiveIncomeTaxRateReconciliationPermanentAdjustment
-0.0255
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.0344
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0843
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2065
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.15
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.4350
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0150
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0180
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.99
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.91
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.58
CY2018 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
761369
CY2018 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
233413
CY2018 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
117105
CY2018Q4 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
186505
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
416734
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
636071
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
191.38
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1111887
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
611.20
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
15.91
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
11.90
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
22345
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
20360
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
27718
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
39742
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
29.13
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
32.70
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
42.42
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
77.40
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
282000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
44473
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.10
CY2007Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8050
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
29000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
130000
CY2018 clrb Preferred Stock Convertible Beneficial Conversion Feature And Deemed Dividend On Preferred Stock
PreferredStockConvertibleBeneficialConversionFeatureAndDeemedDividendOnPreferredStock
2241795
CY2017 clrb Preferred Stock Convertible Beneficial Conversion Feature And Deemed Dividend On Preferred Stock
PreferredStockConvertibleBeneficialConversionFeatureAndDeemedDividendOnPreferredStock
1448945
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
10374683
CY2018 dei Trading Symbol
TradingSymbol
CLRB
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4757709
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on July 12, 2018, our stockholders approved an amendment to our certificate of incorporation to affect a reverse split of our common stock at a ratio between 1:5 to 1:10 and authorized the Board to determine the ratio at which the reverse split would be. The Board authorized the ratio of the reverse split, and effective at the close of business on July 16, 2018, the Company implemented a 1-for-10 reverse stock split of its outstanding common stock. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock that the Company is authorized to issue remains unchanged at 80,000,000 and the par value remains at $0.00001 per share. Accordingly, stockholders' equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Files In Submission

Name View Source Status
0001144204-19-009973-index-headers.html Edgar Link pending
0001144204-19-009973-index.html Edgar Link pending
0001144204-19-009973.txt Edgar Link pending
0001144204-19-009973-xbrl.zip Edgar Link pending
clrb-20181231.xml Edgar Link completed
clrb-20181231.xsd Edgar Link pending
clrb-20181231_cal.xml Edgar Link unprocessable
clrb-20181231_def.xml Edgar Link unprocessable
clrb-20181231_lab.xml Edgar Link unprocessable
clrb-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv514137_10k.htm Edgar Link pending
tv514137_ex21-1.htm Edgar Link pending
tv514137_ex23-1.htm Edgar Link pending
tv514137_ex31-1.htm Edgar Link pending
tv514137_ex31-2.htm Edgar Link pending
tv514137_ex32-1.htm Edgar Link pending